- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Sandoz Group
Market Cap: CHF 28.9b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 66.74
7D
-2.4%
1Y
39.4%
Galderma Group
Market Cap: CHF 36.1b
Operates as a dermatology company worldwide.
GALD
CHF 154.95
7D
-2.3%
1Y
6.3%
Novartis
Market Cap: CHF 213.0b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 112.04
7D
-13.5%
1Y
13.3%
Lonza Group
Market Cap: CHF 37.1b
Operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 531.20
7D
-6.3%
1Y
-3.0%